Johnson & Johnson $JNJ Stock: Thurston Springer Miller Herd & Titak Inc. Lowers Position

Key Points

• Thurston Springer Miller Herd & Titak Inc. cut its Johnson & Johnson position by 73.1% in the third quarter, selling 6,065 shares and retaining 2,236 shares valued at approximately $592,000.
• Johnson & Johnson reported third-quarter adjusted EPS of $2.59, beating estimates, while revenue rose 5.9% to $25.4 billion. Management also raised its 2026 revenue and adjusted-EPS guidance, supported by growth in Innovative Medicine.
• Investors remain focused on weaker MedTech growth, potential orthopedic-business separation costs, litigation and acquisition charges, and recent insider selling. The company declared a $1.34 quarterly dividend, or $5.36 annually.

Thurston Springer Miller Herd & Titak Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 73.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,236 shares of the company's stock after selling 6,065 shares during the period. Johnson & Johnson comprises 1.0% of Thurston Springer Miller Herd & Titak Inc.'s holdings, making the stock its 13th largest position. Thurston Springer Miller Herd & Titak Inc.'s holdings in Johnson & Johnson were worth $592,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Silver Coast Investments LLC raised its position in Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV grew its position in shares of Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares during the period. Triumph Capital Management grew its position in shares of Johnson & Johnson by 1.6% in the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after purchasing an additional 39 shares during the period. Kwmg LLC increased its stake in shares of Johnson & Johnson by 1.7% during the third quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after purchasing an additional 39 shares in the last quarter. Finally, Denali Advisors LLC increased its stake in shares of Johnson & Johnson by 1.2% during the second quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock worth $839,000 after purchasing an additional 40 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted EPS of $2.59, above the $2.53 consensus, while revenue increased 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth driver, with strong oncology performance, renewed immunology growth and rising demand for TREMFYA. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and adjusted EPS of $11.05-$11.15. The guidance increase supports the view that pharmaceutical momentum is offsetting near-term device-market pressure. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: The company maintained its shareholder-return appeal by declaring a $1.34 quarterly dividend, equivalent to $5.36 annually and roughly a 2.2% yield at the referenced price. Johnson & Johnson dividend announcement
• Neutral Sentiment: Johnson & Johnson is leaning toward spinning off its hips-and-knees orthopedic business, with a targeted completion around mid-2027. The move could sharpen the company’s portfolio, but investors are focused on execution and possible earnings dilution from the separation and recent drug deals. Johnson & Johnson MedTech orthopedics spinoff
• Negative Sentiment: MedTech growth was only about 2.5% operationally and missed expectations, particularly in cardiovascular and surgery businesses outside the United States. Middle East-related budget and market disruptions added pressure, raising concerns about the segment’s growth trajectory. Johnson & Johnson MedTech-focused earnings coverage
• Negative Sentiment: Reported third-quarter profit was heavily reduced by charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. GAAP EPS fell to approximately $0.09, overshadowing the adjusted earnings beat. Johnson & Johnson Q3 earnings call highlights
• Negative Sentiment: Royal Bank of Canada lowered its price target from $290 to $280, while Erste Group reduced its 2027 EPS estimate to $12.65 from $12.83. These revisions signal that analysts see less near-term upside despite retaining generally constructive ratings.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $4.55 on Wednesday, hitting $253.16. 4,213,989 shares of the company were exchanged, compared to its average volume of 7,974,220. The stock has a market capitalization of $610.09 billion, a price-to-earnings ratio of 29.31, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. The company has a 50-day moving average price of $265.89 and a 200 day moving average price of $249.37. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The firm had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The business's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.09 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is presently 62.11%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 29th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. HSBC raised their target price on Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. TD Cowen lifted their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Finally, Morgan Stanley boosted their price target on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $273.61.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.